Filing Flows › Akebia Therapeutics (AKBA) › R&D spending
Akebia Therapeutics (AKBA) R&D spending by quarter
Akebia Therapeutics' R&D spending was $16.2M in Q3 2026 (third quarter 2026), +15% from Q2 2026. Over the last 7 quarters it ranged from $9.8M (Q1 2025) to $26.6M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $16.2M | +15% | +8% |
| Q2 2026 | $14.1M | -5% | +28% |
| Q1 2026 | $14.8M | -44% | +52% |
| Q4 2025 | $26.6M | +78% | — |
| Q3 2025 | $14.9M | +36% | — |
| Q2 2025 | $11.0M | +13% | — |
| Q1 2025 | $9.8M | — | — |
Q3 2026 at a glance
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Akebia Therapeutics' R&D spending?
Akebia Therapeutics' R&D spending was $16.2M in Q3 2026 (third quarter 2026), +15% from Q2 2026.
How has Akebia Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $9.8M (Q1 2025) to $26.6M (Q4 2025).